Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Effect of Empagliflozin on the Renin-angiotensin System in Patients With Chronic
This study will be a prospective, clinical pilot study in CKD patients to show whether
Empagliflozin in addition to ACEi treatment significantly increases Ang 1-7 levels compared
to ACEi treatment alone.
Null and alternative hypotheses:
H0: Empagliflozin in addition to ACEi treatment does not increase Ang 1-7 levels more than
ACEi treatment alone.
H1: Empagliflozin in addition to ACEi treatment significantly increases Ang 1-7 levels
compared to ACEi treatment alone
Methodology:
Two groups of 24 chronic kidney disease (CKD) patients, respectively, with and without type 2
diabetes will be randomized into the study medication or placebo group. The number of
patients per treatment arms is n = 12. Included and consented patients will be subjected to
an initial 2-week run-in period for conversion of current RAS blocking medications to ACEi
therapy with enalapril or ramipril and respective dose titration to 10 mg enalapril 2 x daily
and 10 mg ramipril 1 x daily. Additional antihypertensive medication will be standardized as
feasible, with the primary goal of keeping blood pressure as recommended by KDIGO. Following
the 2-week run-in phase, all study patients will be subjected to blood collection including
the first RAS quantification (RAS Fingerprint) and assessment of HDL composition, as well as
urinary analysis and bioimpedance fluid status assessment (BCM measurement). Subsequently,
patients will be randomized to either receive empagliflozin (at a dose of 10 mg daily) or
placebo. Subsequently, biweekly study visits including electrolyte and glucose (plasma and
urine) monitoring as well as BCM measurement will take place. After 12 weeks of study
medication intake, a concluding study visit will be scheduled for final RAS quantification
(RAS Fingerprint) and HDL analyses as well as final blood and urinary analysis and BCM
measurement. Initially, blood and urine will be collected at the clinical visit as part of
the routine blood obtainment (no additional effort on patients). From these routine
measurements we will be able to extract information regarding the patient's current CKD stage
as well as other relevant laboratory parameters (e.g. HbA1c, UACR, etc.). Furthermore, we
will document the patient's current medication and significant comorbidities.
Primary analysis variable/endpoint:
The difference of Ang 1-7 increase from baseline between a 3-month treatment with
empagliflozin on top of ACEi treatment compared to ACEi treatment alone
Most important secondary analysis variables/endpoints:
1. Simultaneous quantitative changes of multiple RAS effector angiotensin levels determined
by mass-spectrometry
2. Recurrence of Ang II levels determined by mass-spectrometry
3. HDL parameters (protein composition of HDL)
4. Renal parameters (albuminuria reduction measured by urinary albumin-creatinine ratio
(UACR), renal function (estimated glomerular filtration rate (GFR), serum-creatinine)
5. Urinary electrolyte levels
6. Urinary glucose levels
7. Urinary RAS metabolites (angiotensinogen, ACE and ACE2 levels, ACE2 activity)
8. Blood pressure determined by ambulatory blood pressure measurements
9. Body volume determined by bioimpedance fluid status assessment (BCM measurement)
10. OCR and ECAR in PBMCs determined by Seahorse Flux Analyzer
11. Assessment of reduction of salt sensitivity by using salt sensitivity test with
empagliflozin
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
| Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
| Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
| Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
| Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
| Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
| Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
| Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
| Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
| Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
| Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
| Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
| Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |